Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 6/20 | 0.52 |
| ▸ | PARP1 | P09874 | 5/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13180313 | 0.83 | AR (0.54) | ARPARP1POLBPRMT5SMN1; SMN2 | |
| SCHEMBL11173101 | 0.80 | SMN1; SMN2 (0.69) | ARPARP1POLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL26247290 | 0.79 | AR (0.45) | ARPARP1 | |
| SCHEMBL31690178 | 0.79 | AR (0.45) | ARPARP1 | |
| SCHEMBL13122355 | 0.77 | AR (0.43) | ARPARP1LMNA | |
| SCHEMBL25310888 | 0.76 | AR (0.45) | ARPARP1POLBSMN1; SMN2ALDH1A1 | |
| SCHEMBL25310246 | 0.76 | AR (0.45) | ARPARP1PRMT5WDR77 | |
| SCHEMBL7462930 | 0.76 | PRMT5 (0.68) | ARPARP1POLBPRMT5SMN1; SMN2 | |
| SCHEMBL30231202 | 0.76 | PRMT5 (0.68) | ARPARP1POLBPRMT5SMN1; SMN2 | |
| SCHEMBL13145722 | 0.76 | AR (0.43) | ARPARP1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CHEMOCENTRYX, INC. | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234364-A1 | CCR2 INHIBITORS AND METHODS OF USE THEREOF | CCR2, CCR9, CCR1 | AR 653/4885PARP1 4449/4885POLB 4104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.